Imipenem carries a risk of inducing epilepsy. Imipenem is a newest type of β-lactam antibiotic iminothiramycin, which has a powerful ability to inhibit bacterial cell wall synthesis, with a broader bactericidal spectrum, especially for mixed infections caused by a variety of pathogens, and still possesses potent antimicrobial activity against many cephalosporin-resistant bacteria, but is not suitable for the treatment of meningitis. Imipenem, like other beta-lactam antibiotics, may produce central nervous system side effects with intravenous administration, such as muscle clonus, confusion, or seizures, especially when used in doses exceeding those recommended based on body weight and renal status. However, most of these side effects occur in patients with pre-existing central nervous system disorders and in those with renal impairment. When imipenem is required in patients with central nervous system disorders and renal impairment, it should be used strictly in accordance with the recommended dosage. If central nervous system symptoms have been induced, the dose of the product should be reduced or discontinued and symptomatic treatment such as antiepileptic therapy should be given. Common adverse reactions to imipenem are erythema, rash, nausea, diarrhea, and abnormal liver function. It is contraindicated in people who are allergic to beta-lactam antibiotics. The dosage of Imipenem must be evaluated by a medical professional and individualized according to the patient’s condition.